According to sources India's National Pharmaceutical Pricing Authority is considering a revision of the National List of Essential Medicines (NLEM) to include all live-saving therapies, Business Standard reported.
According to a person familiar with the matter, the regulator is also contemplating revising a provision that would allow the agency to monitor the prices of close substitutes and analogues prescribed along with such life-saving medicines.
The possible decision could have major implications for large drugmakers such as GlaxoSmithKline, Novartis, Pfizer, Ranbaxy and Sun Pharma, which control large shares of the market.
The NPPA's recommendations are expected to go to the Department of Pharmaceuticals in the health ministry next month.
"We want to target those segments where volumes are high because consumption is high," stated an NPPA official, adding "however, there is a huge price parity. The expansion of NLEM will try to address this loophole."
Specifically, the changes proposed by the NPPA target drugs in the anti-infective, cardiac, gastro-intestinal, respiratory, anti-diabetic, analgesic, neurological and gyneacological markets.